Nektar Therapeutics/NKTR

$0.78

9.71%
-
1D1W1MYTD1YMAX

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.

Ticker

NKTR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Howard Robin

Employees

216

Headquarters

San francisco, United States

NKTR Metrics

BasicAdvanced
$148.8M
Market cap
-
P/E ratio
-$1.55
EPS
0.86
Beta
-
Dividend rate

What the Analysts think about NKTR

Analyst Ratings

Majority rating from 4 analysts.
Hold

Price Targets

Average projection from 2 analysts.
124.36% upside
High $3.00
Low $0.50
$0.78
Current price
$1.75
Average price target

NKTR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-190.04% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$24.1M
18.14%
Net income
$-45.8M
-10.37%
Profit margin
-190.04%
-24.13%

NKTR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20.34%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.32
-$0.73
-$0.27
-$0.24
-
Expected
-$0.45
-$0.25
-$0.28
-$0.20
-$0.21
Surprise
-29.27%
189.03%
-4.89%
20.34%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Nektar Therapeutics stock

Buy or sell Nektar Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing